Latest Medical Research News

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Control Bionics has closed its Share Purchase Plan, raising $256,500 and pushing total capital raised to $9.75 million, pending shareholder approval for the final tranche.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Micro-X has captured the first human head images using its innovative carbon nanotube cone beam CT technology, marking a major technical milestone as it launches a multi-centre pilot study aimed at stroke diagnosis.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

Noxopharm’s SOF-16 active ingredient demonstrated potent anti-inflammatory activity in patient-derived samples of systemic lupus erythematosus and rheumatoid arthritis, advancing its Sofra™ platform beyond topical applications.